HSPD1 and COVID-19: Additionally, Hsp60 viability as a biomarker for disease severity and progression will be evaluated through longitudinal proteomic studies, showing its elevation in fatal COVID-19 cases, as well as its promise as a therapeutic target for interventions targeting extracellular Hsp60 neutralization in acute COVID-19 infection and mitochondrial Hsp60 modulation in the so-called “long COVID syndromes”, characterized by persistent endothelial dysfunction as well as other disorders.